LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Gene Linked to Poor Prognosis for Melanoma

By LabMedica International staff writers
Posted on 06 Mar 2013
Print article
A gene has been identified that is present in some patients with melanoma, which appears to make the tumor cells more resistant to treatment.

The gene, Tumor protein p63 (TP63), is unexpectedly expressed in a number of melanoma cases and correlates significantly with a worse prognosis and it is hoped this new understanding of what makes some melanoma cells so difficult to kill will help the development of new therapies.

Scientists at Queen Mary, University of London (UK) analyzed 156 melanoma tissue samples from 129 individuals for expression of the protein p63, which is encoded by the gene TP63. Overall, 19 recurrent melanoma samples and 56 metastatic melanoma tumor samples from 49 individuals, 22 males and 27 females, were analyzed. The median age at diagnosis was 60.6 years and the median follow up for this cohort was 1.52 years. The proportion of p63-positive tumors comprised 10/19 (53%) of recurrent tumors and 37/56 (66%) of metastatic tumors.

Overall mortality for recurrent and metastatic tumors was 45% and melanoma-specific mortality was 37%. Median age of death was 62.4 years with median time to death from first recurrence or metastases was 15 months. The number of cases of melanoma is rising faster than almost any other cancer and one of the main risk factors is ultraviolet light, which comes from the sun or sun beds [tanning bed]. While early-stage melanomas can often be removed by surgery, more advanced melanomas are much harder to treat.

Daniele Bergamaschi, PhD, a senior lecturer in cutaneous research at Queen Mary said, "For most patients where the melanoma has spread beyond the skin, there are few effective treatments and overall survival rates for this disease have not changed much over the past 30 years. To develop better treatments we need to understand the basic biology underpinning why these cells are so resistant to being killed."

Dr. Bergamaschi added, "We did not expect to find the TP63 gene expressed in melanoma. It is not usually found in the melanocytes (skin pigment cells), which are the cells from which melanomas develop. However, it appears in some cases this gene is turned on as the tumor forms, and when it does it is linked to a worse prognosis." The study was published on February 18, 2013, in the Journal of Experimental Medicine.

Related Links:
Queen Mary, University of London


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more